-

05:23:23 PM

BDPT Stock News

BDPT - Bioadaptives Inc

06/23/22 7:00 AM

OTC : BDPT

BioAdaptives, Inc. Seeks to Increase Market Share in $1.9 Billion Global Pet Supplements Market With Canine All-In-One Premium Nutraceutical

via NewMediaWire – BioAdaptives, Inc. (OTCMkts: BDPT), has launched its advanced proprietary supplement for dogs, Canine All-in-One, a daily dose formulation, patterned after its highly successful product for horses, Equine All-In-One. Canine

RHEA-AI

neutral

06/09/22 7:00 AM

OTC : BDPT

BioAdaptives, Inc. Reveals Corporate Strategy for a Strengthened Market Presence, Through Empowerment of Seniors, as Nutraceutical Market Surpasses $454 Billion USD

via NewMediaWire – BioAdaptives, Inc. (OTCMkts: BDPT). In response to urgent and growing inflationary concerns expressed by the latest generation entering

RHEA-AI

neutral

06/02/22 7:00 AM

OTC : BDPT

covid-19

BioAdaptives Sponsors COVID-19 Long Hauler Survey

via NewMediaWire – BioAdaptives, Inc. (OTCMkts: BDPT) announces its sponsorship of the COVID Long Haul Survey conducted by independent medical researcher, Regina Sutton, M.D. Dr. Sutton, who previously summarized her successful use of PluriPain® to

RHEA-AI

neutral

02/25/22 10:00 AM

OTC : BDPT

BioAdaptives Expands Gadolinium Deposition Disease Survey

via NewMediaWire – BioAdaptives, Inc. (OTCMkts: BDPT), In reference to the previous Press Release of February 24, 2022, the Company announced today that it will continue providing Pluripain® and monitoring the use of this product by those

RHEA-AI

neutral

02/24/22 7:00 AM

OTC : BDPT

BioAdaptives Announces Initial Investigation Results Pluripain® Improves Symptoms of Gadolinium Deposition Disease

via NewMediaWire – BioAdaptives, Inc. (OTCMkts: BDPT) announced today positive results from a study conducted by Stanford Medical School Professor, Lorrin Koran, M.D., regarding the use of Pluripain® to manage the symptoms of Gadolinium Deposition

RHEA-AI

neutral

02/03/22 7:00 AM

OTC : BDPT

acquisition

BioAdaptives Acquires Oxygenated Water Technology Patent and Forms Subsidiary, MORO2, Inc., to Create New Products

BioAdaptives, Inc. (OTCMkts: BDPT) announced today that it has entered into a definitive agreement with inventor Thomas

RHEA-AI

positive

01/27/22 6:30 AM

OTC : BDPT

BioAdaptives to Investigate Use of Lung Cleanser for Long-Term Smokers

BioAdaptives, Inc. (OTCMkts: BDPT) announced today that it is commencing preliminary investigation into the clinical utilization of its Lung

RHEA-AI

neutral

01/20/22 6:30 AM

OTC : BDPT

acquisition

BioAdaptives Signs Letter of Intent to Acquire Oxygenated Water Technology Patent

via NewMediaWire – BioAdaptives, Inc. (OTCMkts: BDPT) announced today that it has entered into a Letter of Intent with inventor Thomas J. Mohr, to acquire rights to his U.S.

RHEA-AI

positive

12/15/21 6:30 AM

OTC : BDPT

BioAdaptives' LungFlute Marketing Agreement and New Product

BioAdaptives, Inc. (OTCMkts: BDPT) announced that it has entered into a Marketing Agreement with Acoustic Innovations LLC, the developer of the LungFlute™ OscPEP (Oscillating Positive Expiratory Pressure) medical device. The

RHEA-AI

positive

08/26/21 7:00 AM

OTC : BDPT

BioAdaptives Collaboration with Stanford Professor

BioAdaptives, Inc. (OTCMkts: BDPT) announced the collaboration with Professor Lorrin Koran, M.D., Stanford Medical Center, Stanford, CA. Dr. Edward Jacobs,

RHEA-AI

neutral